The role of platelets CD40 ligand (CD154) in acute coronary syndromes

Thrombosis Research

Volumn 124, Issue 6, 2009, Pages 683-688

  Abu El Makrem, Mona A ^a   Mahmoud, Yehia Z ^a   Sayed, Douaa ^b   Nassef, Noussa M ^b   Abd El Kader, Samir S ^c   Zakhary, Madiha ^c   Ghazaly, Taghreed ^b   Matta, Ragaa ^a  

^a Minia University   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c Assiut University Faculty of Medicine   (Egypt)

Author keywords

Acute Coronary Syndrome; CD154; Flow Cytometry; Platelets

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HEART MOVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; STABLE ANGINA PECTORIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; BLOOD PLATELETS; CASE-CONTROL STUDIES; CD40 LIGAND; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; NITRIC OXIDE; P-SELECTIN;

EID: 70449521293     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.028     Document Type: Article

References (41)

1. Kuo V., and Nassisi D. Unstable angina and non-ST-segment myocardial infarction: An evidence-based approach to management. Mt Sinai J Med 73 1 (2006) 449-468
2. Spagnoli L.G., Elena B., Sangiorgi G., and Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 48 11 (2007) 1800-1815
3. Lutgens E., Lievens D., Beckers L., Donners M., and Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 17 4 (2007) 118-123
4. Schönbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
5. Vishnevetsky D., Kiyanista V.A., and Gandhi P.J. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 38 9 (2004) 1500-1508
6. Antman E.M., and Braunwald E. Acute Myocardial Infarction. In: Braunwald E. (Ed). Heart disease. 5th ed. (1997), Saunders, Philadelphia 1946-1977
7. Schwartz D., and Gold berg A.C. Ischemic Heart Disease. In: Green G.B., Harris I.S., Lin G.A., and Maylank C. (Eds). The Manual Washington of Medical Therapeutic. 31th edition (2004), Lippincott William & Wilkins, New York 92-132
8. Mark D.B., Shaw L., and Harrel F.E. Prognostic value of treadmill exercise score in out patients with suspected coronary arery disease. NEJM 325 12 (1991) 849-853
9. Iskandrian A.E., and Verani M.S. Nuclear Imaging Technique. In: Topol R.J., Califf R.M., Isner J.M., Prystowsky E.N., Swain J.L., Thomas J.D., Thampson P.D., and Young J.B. (Eds). Cardiovascular Medicine. Second edition (2002), Lippincott Williams & Wilkins, Philadelphia 1191-1203
10. Cockcroft D.W., and Gault H.M. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
11. Mizrachi B.E., and Mizrachi B.C. Diabetes Mellitus and related disorders. In: Green G.B., Harris I.S., Lin G.A., and Maylank C. (Eds). The Manual Washington of Medical Therapeutic. 31th edition (2004), Lippincott William & Wilkins, New York 470-492
12. Shiller N.B., Shah P.M., and Crawford M. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, subcommittee on quantitation of two-dimensional echocardiography. J Am Soc Echocardiogr 2 (1989) 358-367
13. Chung B.H., Wilckson T.G., and Fegerst J.T. Preparative isolation and quantitative isolation of plasma lipoprotein rapid and single discontinuous gradient ultra centrifuging in a vertical rotor. J Lipid Res 21 (1980) 284-291
14. Lowrry O.H., Rosepep N.J., Farirac, and Ranela L. Protein measurement with folinphenol reagent. J Biol Chem 13 (1951) 193-265
15. Satoh R. Serum lipid peroxide in cerebro-vascular disorders determined by a new colorimetric method. Clin Chem Acta 90 1 (1978) 37-43
16. Miles E.M. Methods Enzymol 268 (1996) 105
17. Wooton J.A.A. Determination of plasma fibrinogen. Microanalysis in Medical biochemistry. 5th ed. (1974), Churchill Company, London 517-520
18. Yan J.C., Wu Z.G., Kong X.T., Zong R.Q., and Zhan L.Z. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome. Acta Pharmacol Sin 25 2 (2004) 251-256
19. Mason P.J., Chakrabarti S., Albers A.A., Rex S., Vitseva O., Varghese S., et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96 10 (2005) 1365-1369
20. Sibbing D., von Beckerath O., Schömig A., Kastrati A., and von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis 18 4 (2007) 335-339
21. Lutgens E., Lievens D., Beckers L., Donners M., and Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 17 4 (2007) 118-123
22. Tayebjee M.H., Lip G.Y., Tan K.T., Patel J.V., Hughes E.A., and MacFadyen R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96 3 (2005) 339-345
23. Albert K.G., Zimmet P., and Shaw J. Metabolic syndrome: a new worldwide definition. A consensus statement from International Diabetes Federation. Diabet Med 23 5 (2006) 469-480
24. Garlichs C.D., Eskafi S., Raaz D., Schmidt A., Ludwig J., Herrmann M., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86 (2001) 649-655
25. Yan J.C., Wu Z.G., Kong X.T., Zong R.Q., and Li L. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes. Chin Med J 115 4 (2002) 491-493
26. Gurbel P.A., and Bliden K.P. The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. Thromb Res 112 1-2 (2003) 9-12
27. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
28. Vavuranakis M., Latsios G., Aggelis D., Bosinakou I., Karambelas I., Tousoulis D., et al. Randomized comparison of the effects of Aspirin plus clopidogrel versus Aspirin alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 28 6 (2006) 860-871
29. Li D., Liu L., Chen H., Sawamura T., and Mehta J.L. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 816-821
30. Tousoulis D., Antoniades C., Nikolopoulou A., Koniari K., Vasiliadou C., Marinou K., et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 37 8 (2007) 623-628
31. Ohashi Y., Kawashima S., Mori T., Terashima M., Ichikawa S., Ejiri J., et al. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 112 1 (2006) 52-58
32. Schäfer A., Wiesmann F., Neubauer S., Eigenthaler M., Bauersachs J., and Channon K.M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 109 (2004) 1819-1822
33. Davis B., and Zou M. CD40 ligand-dependent tyrosine nitration of prostacyclin synthase in vivo. Circulation 112 (2005) 2184-2192
34. Theroux P. Angina pectoris. In: Goldman L., and Ausiello D. (Eds). Cecil Medicine. 23rd edition (2008), Saunders Elsevier, United State 477-485
35. Davi G., Guagnano M.T., Basili C.G., Marinopiccoli F.A., Michele N.M., Sensi S., et al. platelet activation in obese women role of inflammation and oxidant stress. JAMA 288 (2002) 2008-2014
36. Preston R.A., Coffey J.O., Materson B.J., Ledford M., and Alonso A.B. Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 192 1 (2007) 148-154
37. Fuster V. Atherosclerosis, Thrombosis and Vascular biology. In: Goldman L., and Ausiello D. (Eds). Cecil Medicine. 23rd edition (2008), Saunders Elsevier, United State 472-477
38. Yan J.C., Ma G.S., Zong R.Q., and Zhan L.Z. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 355 1-2 (2005) 191-196
39. Sonmez A., Dogru T., Yilmaz M.I., Ocal R., Ozgurtas T., Kilic S., et al. Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens 27 8 (2005) 629-634
40. Izzi B., Pampuch A., Costanzo S., Vohnout B., Iacoviello L., Cerletti C., et al. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 98 6 (2007) 1276-1284
41. Pignatelli P., Sanguigni V., Lenti L., Loffredo L., Carnevale R., Sorge R., et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Thromb Haemost 5 6 (2007) 1170-1178